Literature DB >> 8985159

Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis.

H Hastrup1, T W Schwartz.   

Abstract

The three main tachykinins, substance P, neurokinin A (NKA), and neurokinin B, are believed to be selective ligands for respectively the NK-1, NK-2 and NK-3 receptors. However, NKA also has actions which cannot be mediated through its normal NK-2 receptor and the synthetic peptide [pGlu6,Pro9]-Substance P9-11--called septide--is known to have tachykinin-like actions despite its apparent lack of binding to any known tachykinin receptor. In the cloned NK-1 receptor expressed in COS-7 cells NKA and septide as expected were poor competitors for radiolabeled substance P. However, by using radiolabeled NKA and septide directly, it was found that both peptides in homologous binding assays as well as in competition against each other in fact bound to the NK-1 receptor with high affinity: Kd values of 0.51 +/- 0.15 nM (NKA) and 0.55 +/- 0.03 nM (septide). It is concluded that NKA and septide are high-affinity ligands for the NK-1 receptor but that they are poor competitors for substance P, which in contrast competes very well for binding with both NKA and septide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8985159     DOI: 10.1016/s0014-5793(96)01337-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  18 in total

1.  Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

3.  Colorectal and cardiovascular effects of [Lys5,MeLeu9,Nle10]-NKA(4-10) in anesthetized macaques.

Authors:  Nadia M J Rupniak; Mary Katofiasc; Edward C Burgard; Karl B Thor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-01       Impact factor: 3.000

4.  Tachykinins and Neurokinin Receptors in Bone Marrow Functions: Neural-Hematopoietic Link.

Authors:  Tilman E Klassert; Shyam A Patel; Pranela Rameshwar
Journal:  J Receptor Ligand Channel Res       Date:  2010-04-01

5.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  NK2 and NK1 receptor-mediated effects of NKA and analogs on colon, bladder, and arterial pressure in anesthetized dogs.

Authors:  Nadia M J Rupniak; Mary Katofiasc; Lesley Marson; Karl B Thor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-26       Impact factor: 3.000

Review 7.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

8.  Prokinetic effects of neurokinin-2 receptor agonists on the bladder and rectum of rats with acute spinal cord transection.

Authors:  Lesley Marson; Karl B Thor; Mary Katofiasc; Edward C Burgard; Nadia M J Rupniak
Journal:  Eur J Pharmacol       Date:  2017-12-10       Impact factor: 4.432

9.  Endogenous peptidergic modulation of perisynaptic Schwann cells at the frog neuromuscular junction.

Authors:  M J Bourque; R Robitaille
Journal:  J Physiol       Date:  1998-10-01       Impact factor: 5.182

10.  Substance P induces inflammatory responses involving NF-κB in genetically diabetic mice skin fibroblasts co-cultured with macrophages.

Authors:  Tao Ni; Yushu Liu; Yinbo Peng; Ming Li; Yong Fang; Min Yao
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.